Proactive Investors - Run By Investors For Investors

Cellmid expecting record sales in December quarter, shares up 15%

The company sells anti-ageing products for hair, skin and body.
growth concept shown with stairs going up
It has multiple brands and sells these products into Australia, Japan, US and China

Cellmid Ltd (ASX:CDY) expects its sales revenue to reach a record $2.2 million for the December quarter.

This is supported by a recent sales event on its Japanese television shopping channel that delivered sales revenue of $1.1 million.

Cellmid’s Jo-Ju® branded Japanese hair growth products have proven to be one of the most successful cosmetics ever on the Japanese television shopping channel.

READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

Cellmid’s CEO Maria Halasz said: “With around 50,000 QVC customers, a large number of them regulars, we have a strong following for our Jo-Ju® products in Japan.

“We intend to build on this to maximise the potential for our recently launched évolis® products in multiple sales channels in Japan.”

Switch to plastic bottles to increase profit margin

Cellmid recently changed packaging for its Jo-Ju® lotions from glass to plastic bottles.

As a result, net profit margins are expected to increase by around 10%, whilst manufacturing time reduced from seven months to as little as three months.

This, in turn, will allow better utilisation of working capital.

Smoothing out sales going forward

Major sales events, such as those on Japenese television channel QVC currently represent material components of sales revenue, resulting in significant fluctuations in quarterly sales.

Cellmid has been working towards setting up distribution in channels that deliver more even monthly sales.

Furthermore, the company has been actively building distribution in other channels and geographies to reduce reliance on sales from TV shopping.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use